Treatment of Rheumatoid Arthritis with Golimumab Against the Disease Modifying Anti-Rheumatic Drugs and Infliximab Resistance

Authors

  • Kambham Venkateswarlu Department of Pharmacoinformatics, 2Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Vaishali-844102, Bihar, India.
  • Rajuprasad Yadav Department of Pharmacoinformatics, 2Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, Vaishali-844102, Bihar, India.

Keywords:

Cytokines, Efficacy, Golimumab, Multidrug resistance, Rheumatoid arthritis

Abstract

The safety and efficacy of Golimumab 50 mg (GLMB), for the treatment of rheumatoid arthritis (RA), was investigated by selecting the patients with resistance against the Infliximab and disease modified anti-rheumatic drugs (DMARDs). The patients with resistance to the Infliximab and DMARDs about 50 members were selected and divided into 2 groups as group A and group B. The investigational drug GLMB and placebo were administered to the group A and group B respectively. At predetermined intervals, the samples were collected and analyzed for the concentration of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) present in the synovial fluid. After administration of test drug and placebo, the samples were collected at regular intervals of every 4 weeks upto 24 weeks and analyzed. The concentrations of TNF-α and IL-6, before and after administration of test drug, were compared and observed that the GLMB showed better efficacy than that of the placebo. It could be concluded from the results that the safety and efficacy of the investigational product has been achieved.

Downloads

Download data is not yet available.

References

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW, Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Annals of the Rheumatic Diseases 2002; 61(Suppl 2): ii2-ii7. 2. Pavelka K, Kavanaugh AF, Rubbert-Roth A, Ferraccioli G. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease -modifying anti-rheumatic drugs. Rheumatology 2012; 51(Suppl 2): v12-v21.

Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Research & Therapy 2009; 11(Suppl 1): 1-12. 4. Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the ‘side effects’ or risks of RA leads to underestimation of the benefit/risk of therapies. Clinical and Experimental Rheumatology 2004; 22(5 Suppl 35): S2-S11.trends over 40 years. ArthritisRheum 2003; 48(1): 54-58. 6. Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, Cerhan JR. Mortality risk associated with rheumatoidarthritis in a prospective cohort of older women: results from the Iowa Women’s Health Study. Annals of the Rheumatic Diseases 2002; 61(11): 994-999. 7. Srirangan S, Choy EH. The Role of Interleukin 6 in the Pathophysiology of Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease 2010; 2(5): 247-256. 8. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Achieves of Internal Medicine 1999; 159(21): 2542-2550.

Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery 2003; 2(6): 473-88. 10. Lipsky PE, Van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. [Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group]. The New England Journal of Medicine 2000; 343(22): 1594-1602. 11. Favalli EG, Bugatti S, Biggioggero M, Caporali R. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Research International 2014; 2014: 831603. 12. Morgan C, Lunt M, Brightwell H, Caporali R. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Annals of the Rheumatic Diseases 2003; 62(1): 15-9.

Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker JP, Chatard C, Dulieu V, Bouvier M, Carli PM, Tavernier C. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocyews of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. British Journal of Rheumatology 1996; 35: 430-435.

Curtis JR, Singh JA. The Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics 2011; 33(6): 679-707.

Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Current Pharmaceutical Design 2011; 17(29): 3141-54.

Hennigan S, Kavanaugh A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management 2008; 4(4): 767-775.

Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011; 2011: 765624.

Published

2021-12-02

How to Cite

Kambham , V., & Yadav, R. . (2021). Treatment of Rheumatoid Arthritis with Golimumab Against the Disease Modifying Anti-Rheumatic Drugs and Infliximab Resistance. UPI Journal of Chemical and Life Sciences, 1(1), 59–65. Retrieved from https://uniquepubinternational.com/journals/index.php/jcls/article/view/45

Issue

Volume-1, Issue-1, 2018

Section

Research Article(s)
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © Author(s) retain the copyright of this article.